ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2012
Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Impact of pre-transplant malignancy on outcomes in kidney transplant recipients: an updated meta-analysis with systematic review.World journal of urology · 2024Pooled it
- Pooled it
- Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Cancer medicine · 2015Pooled it
- Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.BMJ (Clinical research ed.) · 2014Pooled it
- The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure.Kidney international · 2014Trial
- Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized, single-center trial at 10 years.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Trial
- Evaluation of everolimus pharmacokinetic monitoring based on trough concentration and area under the blood concentration time curve in kidney transplantation.BMC nephrology · 2026Article
- Tacrolimus-Sirolimus Combined Exposure and Acute Rejection in Kidney Transplant Recipients Undergoing Early Conversion to Sirolimus: A Multicenter Retrospective Cohort Threshold Analysis.Journal of clinical medicine · 2025Article
- mTOR/HIF-1α-associated scleral metabolic reprogramming by Mingshi formula in form-deprivation myopia.Scientific reports · 2025Article
- Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients.Journal of clinical medicine · 2024Article
- Kidney Aging and Chronic Kidney Disease.International journal of molecular sciences · 2024Review
- Non-melanoma skin cancer outcomes in kidney transplant recipients converted from calcineurin inhibitors to mTOR inhibitors: a systematic review.Postepy dermatologii i alergologii · 2023Review
- Inconsistencies in the association of clinical factors with the choice of early steroid withdrawal across kidney transplant centers: A national registry study.Clinical transplantation · 2021Article
- Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study.International urology and nephrology · 2019Observational
- The Effects of Short-Term Immunosuppressive Therapy on Redox Parameters in the Livers of Pregnant Wistar Rats.International journal of environmental research and public health · 2019Article
- Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study.Transplantation · 2018Article
- Article
- Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.Journal of the American Society of Nephrology : JASN · 2017Article
- Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study.Transplantation direct · 2016Article
- Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2013Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
Inhibitors of the mammalian target of rapamycin (mTOR), sirolimus and everolimus, reduce the incidence of acute rejection following kidney transplantation, but their impact on clinical outcomes beyond 2 years after transplantation is unknown. We examined risks of mortality and allograft loss in a prospective observational study of 993 prevalent kidney transplant recipients who enrolled a median of 72 months after transplantation. During a median follow-up of 37 months, 87 patients died and 102 suffered allograft loss. In the overall population, use of mTOR inhibitors at enrollment was not associated with altered risk of allograft loss, and their association with increased mortality was of borderline significance. However, history of malignancy was the strongest predictor of both mortality and therapy with an mTOR inhibitor. Among patients without a history of malignancy, use of mTOR inhibitors was associated with significantly increased risk of mortality in propensity score-adjusted (hazard ratio [HR] 2.6; 95% CI, 1.2, 5.5; p = 0.01), multivariable-adjusted (HR 3.2; 95% CI, 1.5, 6.5; p = 0.002) and one-to-one propensity score-matched analyses (HR 5.6; 95% CI 1.2, 25.7; p = 0.03). Additional studies are needed to examine the long-term safety of mTOR inhibitors in kidney transplantation, especially among recipients without a history of malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.